788136-89-0

Basic information

• Product Name: 4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate
• Synonyms: 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinol 6-acetate;4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate;6-Quinazolinol,4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-, 6-acetate;Gefitinib interMediate VI;Gefitinib IMpurity VIII;Gefitinib Impurity 5;4-((3-Chloro-4-fluorophenyl);-7-methoxyquinazolin-6-yl acetate
• CAS NO: 788136-89-0
• Molecular Formula: C₁₇H₁₃ClFN₃O₃
• Molecular Weight: 361.75
• Mol File: 788136-89-0.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 471.5 °C at 760 mmHg
• Flash Point: 238.9 °C
• Appearance: /
• Density: 1.425
• Refractive Index: 1.649
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 5.22±0.30(Predicted)
• CAS DataBase Reference: 4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate(788136-89-0)
• EPA Substance Registry System: 4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate(788136-89-0)

Safety Data

• Hazardous Substances Data: 788136-89-0(Hazardous Substances Data)

Usage

Description

4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate is a chemical compound that serves as an impurity in Gefitinib (G304000), an antineoplastic drug used for treating cancer.

Uses

Used in Pharmaceutical Industry:
4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate is used as an impurity in the production of Gefitinib (G304000), an antineoplastic drug. It is important to monitor and control the presence of this impurity to ensure the safety and efficacy of the final drug product.

InChI:InChI=1/C17H13ClFN3O3/c1-9(23)25-16-6-11-14(7-15(16)24-2)20-8-21-17(11)22-10-3-4-13(19)12(18)5-10/h3-8H,1-2H3,(H,20,21,22)

Upstream product

• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 20357-25-9 6-nitroveratraldehyde 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 179688-53-0 (4-hydroxy-7-methoxyquinazolin-6-yl) acetate 
• 31839-21-1 2-amino-5-hydroxy-4-methoxybenzoic acid 
• 26791-93-5 methyl 4,5-dimethoxy-2-nitrobenzoate 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 
• 367-21-5 3-chloro-4-fluorophenylamine 
• 179688-52-9 4,6-dihydroxy-7-methoxyquinazoline 
• 26759-46-6 methyl 2-amino-4,5-dimethoxybenzoate 
• 93-07-2 Veratric acid 
• 3943-77-9 ethyl veratrate 
• 100905-33-7 ethyl 2-nitro-4,5-dimethoxybenzoate 
• 20323-74-4 2-carboethoxy-4,5-dimethoxyaniline 

Downstream Products

• 1450754-57-0 6-(2-(3-(but-3-ynyl)-3H-diazirin-3-yl)ethoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine 
• 1428015-62-6 6-(2-aminoethoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine 
• 1221965-74-7 M 527301 
• 1438071-81-8 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo [4,3-a]pyrazin-7(8H)-yl)propoxy)quinazolin-4-amine 
• 1438075-40-1 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(tetrahydro-2H-[1,4]dioxino[2,3-c]pyrrol-6(3H)-yl)propoxy)quinazolin-4-amine 
• 1438071-99-8 N-(3-chloro-4-fluorophenyl)-6-(3-((1R,5S)-1-(dimethylamino)-3-azabicyclo[3.1.0]hexan-3-yl) propoxy)-7-methoxyquinazolin-4-amine 
• 1438071-93-2 (1R,5S)-3-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)-3-azabicyclo[3.1.0]hexan-1-ol 
• 1438072-05-9 N-(3-chloro-4-fluorophenyl)-6-(3-(5.6-dihydro-[1,2,4]triazolo[4.3-a]pyrazin-7(8H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438071-87-4 N-(3-chloro-4-fluorophenyl)-6-(3-(3-ethyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438074-10-2 N-(3-chloro-4-fluorophenyl)-6-(3-(2,3-dimethyl-6,7-dihydro-2H-pyrazolo[4,3-c]pyridine-5(4H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438074-04-4 N-(3-chloro-4-fluorophenyl)-6-(3-(1,3-dimethyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438073-98-3 N-(3-chloro-4-fluorophenyl)-6-(3-(hexahydrofuro[3,4-c]pyridin-5(3H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438073-92-7 N-(3-chloro-4-fluorophenyl)-6-(3-(hexahydro-[1,4]dioxino[2,3-c]pyridin-6(7H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438073-86-9 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(octahydroisoquinolin-2(1H)-yl)propoxy)quinazolin-4-amine 

Relevant articles and documents

Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors

Multi-target, especially dual-target, drug design has become a popular research field for cancer treatment. Development of small molecule dual-target inhibitors through hybridization strategy can provide highly potent and selective anticancer agents. In this study, three series of quinazoline derivatives bearing a benzene-sulfonamide moiety were designed and synthesized as dual EGFR/CAIX inhibitors. All the synthesized compounds were evaluated against epidermoid carcinoma (A431) and non-small cell lung cancer (A549 and H1975) cell lines, which displayed weak to potent anticancer activity. In particular, compound 8v emerged as the most potent derivative against mutant-type H1975 cells, which exhibited comparable activity to osimertinib. Importantly, 8v exhibited stronger anti-proliferative activity than osimertinib against H1975 cells under hypoxic condition. Kinase inhibition studies indicated that 8v showed excellent inhibitory effect on EGFRT790M enzyme, which was 41 times more effective than gefitinib and almost equal to osimertinib. Mechanism studies revealed that 8v exhibited remarkable CAIX inhibitory effect comparable to acetazolamide and significantly inhibited the expression of p-EGFR as well as its downstream p-AKT and p-ERK in H1975 cells. Notably, 8v was found to inhibit the expression of CAIX and its upstream HIF-1α in H1975 cells under hypoxic condition. Molecular docking was also performed to gain insights into the ligand-binding interactions of 8v inside EGFRWT, EGFRT790M and CAIX binding sites.

Novel tinib-type compound, preparation method and application thereof

The invention provides a novel tinib-type compound shown as a structural formula (I), wherein R1 is selected from aryl or ceteroary the aryl or ceteroary is substituted by one or more of alkyl, halogen, aryl, alkynyl, cyano, trifluoromethyl, methoxy and halogenated benzyl; R2 is 1,4,7,10-tetraazacyclododecane or 1,4,7-triazacyclononane. The invention also provides application of the compound in preparation of antitumor medicines. The novel tinib-type compound has an obvious inhibiting effect for A549 cell lines, apoptosis of A549 cells can be obviously enhanced, and the effect is obviously superior to that of gefitinib. (The structural formula is shown in the specification).

Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold

Adenosine triphosphate (ATP)-competitive inhibitors of the epidermal growth factor receptor (EGFR) have provided a significant improvement in the disease outcome of nonsmall cell lung cancer (NSCLC). Unfortunately, some marketed drugs affect a transient beneficial response in EGFR mutant NSCLC patients. We reported a series of potential EGFR inhibitors through incorporation of macrocyclic polyamine into 4-anilinoquinazoline scaffold. It is expected that anilinoquinazoline part effectively bind to EGFR domain, while ATP molecules are captured by a macrocyclic polyamine moiety. In vitro experiments exhibited that most of tested compounds suppressed tumor cell proliferation more strongly than Gefitinib and Lapatinib (dual inhibitor of EGFR/HER2) as controls. In kinase assays, the compound 1f showed excellent dual inhibition activity toward EGFRWT (IC50 = 1.4 nM) and HER2 (IC50 = 2.1 nM). In vivo pharmacology evaluation of 1f showed significant antitumor activity (TGI = 44.2%) in A549 xenografts mice. The current work provided a feasible solution to optimize anilinoquinazoline-based inhibitors.